Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dichotomies, such as reconstructive vs aesthetic surgery and medical vs cosmetic dermatology, can distort meanings of surgical procedures. This can compromise the value of procedures themselves and practices for their reimbursement.
AMA J Ethics. 2018;20(12):E1188-1194. doi:
10.1001/amajethics.2018.1188.
Denisse Rojas Marquez, MD, MPP and Hazel Lever, MD, MPH
“Very important persons” care contributes to multitiered, racially segregated health service delivery streams that influence clinicians’ conceptions of what patients deserve from them.
AMA J Ethics. 2023;25(1):E66-71. doi:
10.1001/amajethics.2023.66.
Dr Lisa Lehmann joins Ethics Talk to discuss “grateful patient programs,” pressures clinicians face to fundraise on behalf of health care organizations for which they work, and whether “VIP” care really is better for patients.
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023;25(6):E391-397. doi:
10.1001/amajethics.2023.391.
Kimberly A. Singletary, PhD and Marshall H. Chin, MD, MPH
The Roadmap to Advance Health Equity offers specific, actionable antiracist payment reform strategies to help ensure that everyone can receive good health services and optimize their health.
AMA J Ethics. 2023;25(1):E55-65. doi:
10.1001/amajethics.2023.55.